Market Overview

Can-Fite BioPharma Reports $4M Deal With Kyongbo Pharm


Can-Fite BioPharma (NYSE: CANF) announced a new deal with Kyongbo Pharm to distribute the drug Piclidenoson for Psoriasis in South Korea, receiving $4 million payment upfront.

For the exclusive distribution rights to sell Piclidenoson in South Korea, Kyongbo Pharm is making a total upfront payment of $750,000 to Can-Fite, with additional payments of up to $3,250,000 upon achievement of certain milestones.

"We are very excited to sign this distribution agreement with Kyongbo, a highly prestigious company in South Korea and we believe that they are the right partner for us to penetrate the Korean market in the indication of psoriasis," stated Sari Fishman, VP business development of Can-Fite BioPharma.

Can-Fite BioPharma shares were trading up 13.19% at $3.26 in Thursday’s pre-market session. The stock has a 52-week high of $25.95 and a 52-week low of 38 cents.

Related Links:

Can-Fite BioPharma Appeals Lawsuit Against Venture Capital Firm

Can-Fite Abstract Selected For Liver Conference, Stock Jumps More Than 60%

Posted-In: News Contracts


Related Articles (CANF)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

28 Healthcare Stocks Moving In Today's Pre-Market Session

Thursday's Market Minute: Watch For These Earnings